Rate Video

EHA 2020 | Assessing high-risk AML

Nigel Russell • 15 Jun 2020

Acute Myeloid Leukemia Leukemia

Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, explores how high-risk acute myeloid leukemia (AML) can be identified as well as the importance of genomic profiling and minimal residual disease (MRD) in AML assessment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

New and emerging drug targets for older AML patients

Nigel Russell • 14 Jun 2020

Treatment options for high-risk AML

Nigel Russell • 16 Jun 2020

Moving towards personalized therapy for AML

Nigel Russell • 18 Apr 2016

Updates from UK NCRI AML18

Nigel Russell • 15 Jun 2020

Related Videos

Impact of MMRD and ELN genetic classification in outcomes for patients with AML underoging alloHCT

Muhammad Husnain • 17 Feb 2021

SIERRA trial updates: apamistamab in AML

Tania Jain • 12 Feb 2021

CAR-T vs. BiTEs in B-cell malignancies

Marion Subklewe • 11 Feb 2021

Flotetuzumab as salvage therapy for primary induction failure and early AML

Ibrahim Aldoss • 11 Feb 2021